For individuals grappling with rare diseases, finding effective treatment options can be an overwhelming challenge. The conventional pathways of drug development, tailored for larger patient cohorts, encounter numerous obstacles in the context of rare diseases. This leads to delays in innovation and impedes access to potentially life-changing therapies. Fortunately, the emergence of real-world evidence (RWE) offers a promising solution to overcome these challenges and reshape the landscape of innovation in rare diseases.[1]
The term “rare disease” encompasses a diverse array of conditions affecting a limited number of individuals. This small patient population presents a substantial hurdle for traditional clinical trial design, which relies on large cohorts to establish statistically significant efficacy and safety. Recruiting an adequate number of participants for rare disease trials is a time-consuming and expensive process, often necessitating international collaboration and specialized expertise. Additionally, the heterogeneity of rare diseases, with their varied presentations and disease trajectories, further complicates the development process.[1]
The traditional HTA process relies heavily on data generated from controlled clinical trials, which may not adequately capture the complexities and variabilities associated with rare diseases. Moreover, the rarity of these conditions often means that traditional clinical trials include a limited number of patients, making it challenging to generate statistically significant results. This limitation not only hampers the regulatory approval of new drugs but also affects the subsequent HTA evaluations.[2]
RWE offers a powerful tool to address these challenges and accelerate innovation in rare disease research and development. RWE encompasses data collected outside of traditional clinical trials, including electronic health records, claims databases, patient registries, and wearable devices. RWE empowers regulatory agencies and HTA bodies, offering the potential to streamline the approval and reimbursement processes for innovative drugs in rare diseases.[2,3]
RWE can be used to quantify the unmet medical need by providing valuable insights into the prevalence, burden, and impact of rare diseases. This data not only highlights the necessity for new treatment options but also informs cost-effectiveness analyses, estimating the costs associated with rare disease management and potential cost savings from innovative treatments. Additionally, RWE contributes to evaluating the long-term value of therapies, offering insights into their impact on patient outcomes and healthcare utilization. This comprehensive approach aids HTA bodies in assessing the overall value proposition of new therapies, ultimately expediting access to effective treatments for patients in need.[3]
RWE significantly drives innovation for rare diseases, offering diverse benefits. Firstly, RWE can be used to identify and recruit patients who meet specific inclusion criteria, even for geographically dispersed populations, leading to faster and more efficient trial completion. Additionally, RWE supports adaptive pathways that align with personalized medicine. This approach allows continuous learning and adaptation based on real-world experiences, tailoring treatments to individual patient characteristics and needs.[3,4]
The integration of RWE into HTA processes brings forth a range of advantages, yet it is not without its challenges. Notably, the quality and standardization of real-world data emerge as critical considerations, demanding continuous efforts to establish common standards and enhance data quality for credible HTA evaluations. Additionally, the reliance on patient data from real-world settings in RWE necessitates a delicate balance between data access and patient confidentiality, highlighting the ongoing challenge of addressing privacy and ethical concerns.[3]
Education and adoption present another layer of complexity, with stakeholders such as regulatory agencies, HTA bodies, healthcare professionals, and pharmaceutical companies requiring comprehensive awareness of the benefits and limitations of RWE. This underscores the need for active promotion and facilitation of RWE adoption in decision-making processes. In the context of rare diseases, these challenges are amplified, prompting innovative approaches to evidence generation.[3]
To fully harness the potential of RWE in rare disease research and HTA, the establishment of a robust infrastructure is imperative. This involves standardizing and harmonizing data collection, analysis, and reporting across different sources to ensure reliable and comparable evidence. Investment in technologies that facilitate data sharing and integration from diverse sources is essential for enhanced data capture. Building trust in RWE necessitates transparency in data sources, methodologies, and limitations, requiring open dialogue with patients, researchers, and HTA bodies. Additionally, clear regulatory guidelines and frameworks for utilizing RWE in HTA decisions are crucial, providing developers and researchers with the necessary clarity and fostering greater use of RWE.[4,5]
The integration of RWE into HTA has the potential to reshape the landscape of rare disease innovation. By providing a more comprehensive understanding of treatment effectiveness, safety, and cost-effectiveness in real-world settings, RWE can address the limitations of traditional clinical trials and expedite the development and access to innovative therapies for rare diseases.
Become A Certified HEOR Professional – Enrol yourself here!
References
- Dang A. Real-World Evidence: A Primer. Pharmaceut Med. 2023 Jan;37(1):25-36.
- Graili P, Guertin JR, Chan KKW, Tadrous M. Integration of real-world evidence from different data sources in health technology assessment. J Pharm Pharm Sci. 2023 Jul 17;26:11460.
- Hampson G, Towse A, Dreitlein WB, et al. Real-world evidence for coverage decisions: opportunities and challenges. Journal of comparative effectiveness research. 2018 Dec;7(12):1133-43.
- Field MJ, Boat TF. Development of new therapeutic drugs and biologics for rare diseases. InRare Diseases and Orphan Products: Accelerating Research and Development 2010. National Academies Press (US).
- Boat TF, Field MJ, editors. Rare diseases and orphan products: accelerating research and development. National Academies Press; 2011 Apr 3.